Paper - WANFANG MED ONLINE

You Position: Home > Paper

Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy

( views:8, downloads:0 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 18

DOI:: 10.1097/CM9.0000000000002371

Key Word:: Esophageal cancer;Immune checkpoint inhibitor;Immunotherapy;Esophageal cancer;Immune checkpoint inhibitor;Immunotherapy

Abstract： Esophageal cancer (EC) has a high incidence and poor prognosis. The two major histological types, squamous cell carcinoma and adenocarcinoma, differ in their epidemiology and treatment options. Patients with locally advanced EC benefit from multimodal therapy concepts including neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and perioperative chemotherapy. Currently, immunotherapy for the solid tumor is a hot spot. Treatment with adjuvant immune checkpoint inhibitors (ICIs) is the first immunotherapy for resectable EC listed in the latest National Comprehensive Cancer Network Guidelines for the Esophageal and Esophagogastric Junction Cancers. Recent clinical trials have established ICIs for three treatment models of resectable EC. Their short-term results demonstrated ideal efficacy and tolerable toxicity, though some concerns remain. This review summarizes the novel data on the ICIs for resectable EC and lists the registered related clinical trials. Hopefully, this review can provide a reference for ongoing research on the treatment options for resectable EC.

Reference

[1]Esdy N, Rozali,Stanleyson V, Hato,Bruce W, Robinson,etc.Programmed death ligand 2 in cancer-induced immune suppression.[J].2012,2012.
[2]Sage PT,Sharpe AH,Francisco LM.The PD-1 pathway in tolerance and autoimmunity.[J].2010,236.
[3]Arnold, Melina,Soerjomataram, Isabelle,Ferlay, Jacques,etc.Global incidence of oesophageal cancer by histological subtype in 2012[J].2015,64(3).
[4]Xi Wang,Bo Zhang,Xuelian Chen,etc.Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody[J].2019,10(6).
[5]Dermani Fatemeh K.,Samadi Pouria,Rahmani Golebagh,etc.PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy[J].2019,234(2).
[6]Weimin,Zhang,Ruoxi,Hong,Lin,Li,etc.The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment.[J].2018,17(1).
[7]Xiao,Wu,Xiurong,Ke,Yangpeng,Ni,etc.Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.[J].2020,2020.
[8]Wang, Jun,Sanmamed, Miguel F.,Datar, Ila,etc.Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3[J].2019,176(1/2).
[9]Nakamura,K.,Kato,K.,Igaki,H.,etc.Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study)[J].2013,43(7).
[10]Cha, Jong-Ho,Chan, Li-Chuan,Li, Chia-Wei,etc.Mechanisms Controlling PD-L1 Expression in Cancer[J].2019,76(3).
[11]Al-Batran, Salah-Eddin,Homann, Nils,Pauligk, Claudia,etc.Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra[J].2019,393(10184).
[12]Dudley, Jonathan C.,Lin, Ming-Tseh,Le, Dung T.,etc.Microsatellite Instability as a Biomarker for PD-1 Blockade[J].2016,22(4).
[13]Xiao-Fei, Zhang,Ke, Pan,De-Sheng, Weng,etc.Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis.[J].2016,(18).
[14]Reynolds JV,Preston SR,O’Neill B,etc.ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)[J].2017,17(1).
[15]Cunningham D,Allum WH,Stenning SP,etc.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.[J].2006,355(1).
[16]Wenjia,Wang,Donglai,Chen,Yuhuan,Zhao,etc.Characterization of LAG-3, CTLA-4, and CD8<sup>+</sup> TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma.[J].2019,7(23).
[17]Rowshanravan, Behzad,Halliday, Neil,Sansom, David M..CTLA-4: a moving target in immunotherapy[J].2018,131(1).
[18]Cao Wei,Chen Hong-Da,Yu Yi-Wen,etc.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].2021,(7).
[19]Heppt, Markus V.,Heinzerling, Lucie,Kaehler, Katharina C.,etc.Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition[J].2017,82.
[20]Alderson, Derek,Cunningham, David,Nankivell, Matthew,etc.Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J].2017,18(9).
[21]Moenig, Stefan,Chevallay, Mickael,Niclauss, Nadja,etc.Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation[J].2018,1434.
[22]Taisuke Yagi,Yoshifumi Baba,Takatsugu Ishimoto,etc.PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer[J].2019,269(3).
[23]Kelly, Ronan J.,Ajani, Jaffer A.,Kuzdzal, Jaroslaw,etc.Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer[J].2021,384(13).
[24]Yang, Hong,Liu, Hui,Chen, Yuping,etc.Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial[J].2018,36(27).
[25]Gebauer, Florian,Kraemer, Max,Bruns, Christiane,etc.Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma[J].2020,146(9).
[26]VanHagen,P.,Hulshof,M.C.C.M.,VanLanschot,J.J.B.,etc.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].2012,366(22).
[27]Li, Chengqiang,Zhao, Shengguang,Zheng, Yuyan,etc.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J].2021,144.
[28]William H, Allum,Sally P, Stenning,John, Bancewicz,etc.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.[J].2009,27.
[29]Lawrence P. Andrews,Ariel E. Marciscano,Charles G. Drake,etc.LAG3 (CD223) as a cancer immunotherapy target[J].2017,276(1).
[30]Girling DJ.Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.[J].2002,359(9319).
[31]Kato Ryo,Yamasaki Makoto,Urakawa Shinya,etc.Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients[J].2018,67(11).
[32].The diverse functions of the PD1 inhibitory pathway.[J].2017,(Spec).
[33]Kumagai Shogo,Togashi Yosuke,Kamada Takahiro,etc.The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies[J].2020,21(11).
[34]Pai, Chien-Chun Steven,Simons, Donald M.,Lu, Xiaoqing,etc.Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity[J].2019,129(1).
[35]Jing Huang,Xingyuan Wang,Yuchen Jiao,etc.Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma[J].2018,24(6).
[36]Melania Scarpa,Matteo Fassan,Andromachi Kotsafti,etc.CD80 expression promotes immune surveillance in Barrett's metaplasia[J].2019,8(10).
[37]Yang Liu,Pan Zheng.Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy[J].2020,41(1).
[38]Willett CG,Minsky BD,Ajani JA,etc.Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.[J].2007,25(24).
[39].Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J].2020,21(6).